# Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

> **NCT04394351** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 102 (actual)

## Conditions studied

- Eosinophilic Esophagitis (EoE)

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT04394351
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-06-02
- **Final completion:** 2024-05-14
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394351, "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04394351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*